Compare Hims and Hers Health Inc (HIMS) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs New York Times Co — how do they compare? Hims and Hers Health Inc trades at $29.25 (market cap $6.55B), while New York Times Co trades at $65.87 (market cap $10.74B). The key difference: New York Times Co is the larger of the two by market cap, and New York Times Co pays a 1.38% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and New York Times Co for 81 Days on average.
| HIMS | NYT | |
|---|---|---|
Market Cap | $6.55B | $10.74B |
Volume | 14,842,814 | 2,096,352 |
Sector | Health | Media |
52-Week High | $62.76 | $85.86 |
52-Week Low | $14.52 | $54.66 |
Typical Hold Time | 21 Days | 81 Days |
Enterprise Value | $7.25B | $10.14B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
The New York Times Company (NYT) trades at $64.90, up 1.3% with a bearish technical signal despite strong fundamental performance. Recent earnings beats and consistent revenue growth to $2.82 billion in 2025 highlight operational strength, though a shareholder lawsuit and AI copyright disputes present headwinds. Analyst consensus is mixed with a $84 price target suggesting 29% upside from current levels.
The stock offers value through earnings growth and dividend yield, but faces sentiment pressure from legal challenges and technical indicators. Key risks include litigation outcomes and competitive pressures in digital media, while institutional ownership trends and positive cash flow generation support the investment case for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
